Docetaxel anhydrous en es it fr

Docetaxel anhydrous Brand names, Docetaxel anhydrous Analogs

Docetaxel anhydrous Brand Names Mixture

  • No information avaliable

Docetaxel anhydrous Chemical_Formula

C43H53NO14

Docetaxel anhydrous RX_link

http://www.rxlist.com/cgi/generic3/docetaxel.htm

Docetaxel anhydrous fda sheet

Docetaxel_anhydrous FDA

Docetaxel anhydrous msds (material safety sheet)

Docetaxel_anhydrous MSDS

Docetaxel anhydrous Synthesis Reference

No information avaliable

Docetaxel anhydrous Molecular Weight

807.879 g/mol

Docetaxel anhydrous Melting Point

232 oC

Docetaxel anhydrous H2O Solubility

Practically insoluble (0.025 mg/L)

Docetaxel anhydrous State

Solid

Docetaxel anhydrous LogP

4.258

Docetaxel anhydrous Dosage Forms

Solution: single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL) docetaxel (anhydrous).

Docetaxel anhydrous Indication

For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Lastly, for use, in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

Docetaxel anhydrous Pharmacology

Docetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Docetaxel anhydrous Absorption

No information avaliable

Docetaxel anhydrous side effects and Toxicity

Oral LD50 in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m2 and the other received 200 mg/m2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.

Docetaxel anhydrous Patient Information

Docetaxel anhydrous Organisms Affected

Humans and other mammals